Hypotonic efficacy and tollerability of Travoprost in patient with glaucoma or ocular hypertension, monotherapy or fixed association beta-blocking not controlled or intollerant.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002252-18-IT

Enrollment

300

Registered

2005-11-03

Start date

2005-09-27

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elevated intraocular pressure reduction in patient with ocular hypertension or open-angle glaucoma. MedDRA version: 6.1 Level: HLGT Classification code 10018307

Interventions

Trade Name: TRAVATAN*COLL. 1FL 40MCG/ML Pharmaceutical Form: Eye drops, solution INN or Proposed INN: Travoprost CAS Number: 157283-68-6 Concentration unit: µg microgram(s) Concentration type: equal C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026